Compounds > tyramine
Page last updated: 2024-11-05

tyramine and Tachycardia

tyramine has been researched along with Tachycardia in 10 studies

Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.

Research Excerpts

ExcerptRelevanceReference
" Norepinephrine was elevated in p75-/- atria, but stimulating norepinephrine release with tyramine produced less tachycardia in p75-/- mice than wild type mice."3.74Regulation of cardiac innervation and function via the p75 neurotrophin receptor. ( Bilimoria, P; Birren, SJ; Gritman, K; Habecker, BA; Linick, C; Lorentz, CU; Woodward, W, 2008)
"We measured norepinephrine spillover (the rate of entry of norepinephrine into the venous circulation) in the arms and legs both before and in response to exposure to three stimuli (the cold pressor test, sodium nitroprusside infusion, and tyramine infusion) in 10 patients with the postural tachycardia syndrome and in 8 age- and sex-matched normal subjects."3.70The neuropathic postural tachycardia syndrome. ( Biaggioni, I; Black, B; Costa, F; Ertl, A; Jacob, G; Robertson, D; Robertson, RM; Shannon, JR; Stein, M; Wathen, M, 2000)
"The tachycardia was abolished by treatment with the beta-antagonist propranolol, demonstrating that it was mediated by catecholamines acting on cardiac beta-receptors."1.31Animal model of neuropathic tachycardia syndrome. ( Appalsamy, M; Carson, RP; Davis, TL; Diedrich, A; Robertson, D, 2001)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19906 (60.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
JAMES, TN1
NADEAU, RA1
Ovchinnikov, V1
Suzuki, G1
Canty, JM1
Fallavollita, JA1
Habecker, BA1
Bilimoria, P1
Linick, C1
Gritman, K1
Lorentz, CU1
Woodward, W1
Birren, SJ1
Jacob, G1
Costa, F1
Shannon, JR1
Robertson, RM1
Wathen, M1
Stein, M1
Biaggioni, I1
Ertl, A1
Black, B1
Robertson, D2
Carson, RP1
Appalsamy, M1
Diedrich, A1
Davis, TL1
Brisse, B1
Bender, F1
Lohmann, FW1
Schüren, KP1
Vigliani, EC1
Cavagna, G1
Locati, G1
Foa, V1
Varagić, VM1
Kazić, T1
Wildenthal, K1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]Phase 1/Phase 28 participants (Actual)Interventional2011-08-15Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
Muscular and Cutaneous Dysfunction in Postural Tachycardia Syndrome[NCT04170725]15 participants (Actual)Interventional2020-01-10Active, not recruiting
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND GASTROINTESTINAL SYMPTOMS: Contribution of Gastrointestinal Peptides[NCT03263819]25 participants (Actual)Observational2017-06-20Completed
Mechanism of Glucose-dependent Insulinotropic Polypeptide (GIP) on Splanchnic Venous Capacitance in Postural Tachycardia Syndrome[NCT05375968]50 participants (Anticipated)Interventional2023-02-25Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention ()
Atenolol0
Placebos0
Droxidopa0

Other Studies

10 other studies available for tyramine and Tachycardia

ArticleYear
THE CHRONOTROPIC ACTION OF TYRAMINE STUDIED BY DIRECT PERFUSION OF THE SINUS NODE THROUGH ITS ARTERY.
    The Journal of pharmacology and experimental therapeutics, 1964, Volume: 144

    Topics: Arteries; Coronary Vessels; Dogs; Injections, Intra-Arterial; Perfusion; Pharmacology; Research; Res

1964
Blunted functional responses to pre- and postjunctional sympathetic stimulation in hibernating myocardium.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 289, Issue:4

    Topics: Animals; Heart; Myocardial Contraction; Myocardial Stunning; Stellate Ganglion; Swine; Sympathetic N

2005
Regulation of cardiac innervation and function via the p75 neurotrophin receptor.
    Autonomic neuroscience : basic & clinical, 2008, Volume: 140, Issue:1-2

    Topics: Adrenergic Uptake Inhibitors; Aging; Animals; Cell Differentiation; Growth Cones; Heart; Heart Atria

2008
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
The neuropathic postural tachycardia syndrome.
    The New England journal of medicine, 2000, Oct-05, Volume: 343, Issue:14

    Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur

2000
Animal model of neuropathic tachycardia syndrome.
    Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:6

    Topics: Adrenergic Agents; Animals; Autonomic Nervous System Diseases; Blood Pressure; Disease Models, Anima

2001
[Experimental findings on tyramine-dependent release of noradrenaline in various parts of the heart under the influence of practolol].
    Zeitschrift fur Kardiologie, 1975, Volume: 64, Issue:10

    Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Heart; Heart Atria; Heart Ventricles;

1975
[Current status of diagnostics in pheochromocytoma].
    Der Internist, 1972, Volume: 13, Issue:2

    Topics: Abdomen; Adrenal Gland Neoplasms; Adult; Anxiety; Catecholamines; Diagnosis; Diagnostic Errors; Epin

1972
Biological effects of nitroglycol on the metabolism of catecholamines. Clinical and experimental observations.
    Archives of environmental health, 1968, Volume: 16, Issue:4

    Topics: Adult; Amphetamine; Animals; Catecholamines; Death, Sudden; Environmental Exposure; Epinephrine; Fla

1968
The acute effect of 6-hydroxy-dopamine on the blood pressure responses to eserine and tyramine in the rat.
    Neuropharmacology, 1970, Volume: 9, Issue:2

    Topics: Animals; Blood Pressure; Drug Antagonism; Female; Male; Nerve Endings; Norepinephrine; Phenethylamin

1970
Responses to cardioactive drugs of fetal mouse hearts maintained in organ culture.
    The American journal of physiology, 1971, Volume: 221, Issue:1

    Topics: Acetylcholine; Animals; Arrhythmias, Cardiac; Bradycardia; Culture Techniques; Digitalis Glycosides;

1971